The phase II COAST study is particularly interesting as improved clinical efficacy was indicated in patients treated with a combination of CD73 and PD-L1 inhibition compared to PD-L1 inhibition alone for unresectable stage III NSCLC after cCRT. The gene discussed is NT5E; the disease is non-small cell lung carcinoma.